MAOA and cancer: For example, SP-2509, identified by Sharma et al. through the high-throughput virtual screening, is a highly potent, reversible, and non-competitive LSD1 inhibitor (Ki = 31 nM, IC50 = 13 nM), shows high selectivity over MAO-A/B (IC50 > 300 μM), and strongly inhibits proliferation against a panel of cancer cell lines [98].